Switch theme
Sign up to access all valuation multiples
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
2016
115
LTM Revenue $17.8M
Last FY EBITDA -$74.3M
-$44.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Generation Bio has a last 12-month revenue (LTM) of $17.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Generation Bio achieved revenue of $19.9M and an EBITDA of -$74.3M.
Generation Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Generation Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $17.8M | XXX | $19.9M | XXX | XXX | XXX |
| Gross Profit | $17.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$74.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -373% | XXX | XXX | XXX |
| EBIT | -$104M | XXX | -$79.2M | XXX | XXX | XXX |
| EBIT Margin | -585% | XXX | -398% | XXX | XXX | XXX |
| Net Profit | -$106M | XXX | -$132M | XXX | XXX | XXX |
| Net Margin | -592% | XXX | -662% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Generation Bio's stock price is $0.
Generation Bio has current market cap of $25.2M, and EV of -$44.8M.
See Generation Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$44.8M | $25.2M | XXX | XXX | XXX | XXX | $-1.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Generation Bio has market cap of $25.2M and EV of -$44.8M.
Generation Bio's trades at -2.3x EV/Revenue multiple, and 0.6x EV/EBITDA.
Equity research analysts estimate Generation Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Generation Bio has a P/E ratio of -0.2x.
See valuation multiples for Generation Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25.2M | XXX | $25.2M | XXX | XXX | XXX |
| EV (current) | -$44.8M | XXX | -$44.8M | XXX | XXX | XXX |
| EV/Revenue | -2.5x | XXX | -2.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | 0.4x | XXX | 0.6x | XXX | XXX | XXX |
| EV/Gross Profit | -2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGeneration Bio's last 12 month revenue growth is -35%
Generation Bio's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.9M for the same period.
Generation Bio's rule of 40 is -2293% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Generation Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Generation Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -35% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -373% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2293% | XXX | -408% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 308% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 498% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Generation Bio acquired XXX companies to date.
Last acquisition by Generation Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Generation Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Generation Bio founded? | Generation Bio was founded in 2016. |
| Where is Generation Bio headquartered? | Generation Bio is headquartered in United States of America. |
| How many employees does Generation Bio have? | As of today, Generation Bio has 115 employees. |
| Who is the CEO of Generation Bio? | Generation Bio's CEO is Dr. Geoffrey McDonough, M.D.. |
| Is Generation Bio publicy listed? | Yes, Generation Bio is a public company listed on NAS. |
| What is the stock symbol of Generation Bio? | Generation Bio trades under GBIO ticker. |
| When did Generation Bio go public? | Generation Bio went public in 2020. |
| Who are competitors of Generation Bio? | Similar companies to Generation Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Generation Bio? | Generation Bio's current market cap is $25.2M |
| What is the current revenue of Generation Bio? | Generation Bio's last 12 months revenue is $17.8M. |
| What is the current revenue growth of Generation Bio? | Generation Bio revenue growth (NTM/LTM) is -35%. |
| What is the current EV/Revenue multiple of Generation Bio? | Current revenue multiple of Generation Bio is -2.5x. |
| Is Generation Bio profitable? | Yes, Generation Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
